参考文献
[1]
BatuwitageBT, KinghamJG, MorganNE, et al.
Inappropriate prescribing of proton pump inhibitors in primary care[J]．
Postgrad Med J,
2007,
83：
66–
68.
[2]
RamirezE, LeiSH, BorobiaAM, et al.
Overuse of PPIs in patients at admission, during treatment, and at discharge in a tertiary Spanish hospital[J].
Curr Clin Pharmacol,
2010,
5：
288–
297.
[3]
MascleeGM, SturkenboomMC, KuipersEJ, et al.
A Benefit-Risk Assessment of the Use of Proton Pump Inhibitors in the Elderly[J].
Drugs Aging,
2014,
31：
263–
682.
[4]
CerretaF, EichlerHG, RasiG, et al.
Drug policy for an aging population-the European Medicines Agency's geriatric medicines strategy[J].
N Engl J Med,
2012,
367：
1972–
1974.
[5]
ChenMM, ZhengSB.
The pharmacokinetic characteristics in the elderly[J].
Geriatr Health Care,
2011,
17：
189–
191.
陈敏敏，郑松柏．
老年人药代动力学的特点[J]．
老年医学与保健，
2011，
17：
189–
191.
[6]
LiuF, ZhengSB.
Focus on safety of proton pump inhibitors[J].
Chin J New Drugs Clin Rem,
2012,
31：
493–
498.
刘菲，郑松柏．
重视质子泵抑制剂的安全性[J]．
中国新药与临床杂志，
2012,
31：
493–
498.
[7]
LiXW, ZhengSB.
Advances in CYP2C19 genetic polymorphism and its impact on efficacy of PPI[J].
Chin J New Drugs Clin Rem,
2013,
32：
775–
779.
李小雯，郑松柏．
CYP2C19基因多态性及其与PPI疗效影响研究进展[J]．
中国新药与临床杂志，
2013,
32：
775–
779.
[8]
HasselgrenG, Hassan-AlinM, AnderssonT, et al.
Pharmacokinetic study of esomeprazole in the elderly[J].
Clin Pharmacokinet,
2001,
40：
145–
150.
[9]
YaoGB.
The new member of PPI-esomeprazole[J].
Chin J Dig,
2002,
22：
233–
235.
姚光弼．
质子泵抑制剂的新成员-埃索美拉唑[J]．
中华消化杂志，
2002,
22：
233–
235.
[10]
DesiletsAR, AsalNJ, DunicanKC, et al.
Considerations for the use of proton-pump inhibitors in older adults[J].
Consult Pharm,
2012,
27：
114–
120.
[11]
FerronGM, PrestonRA, NoveckRJ, et al.
Pharmacokinetics of pantoprazole in patients with moderate and severe hepatic dysfunction[J].
Clin Ther,
2001,
23：
1180–
1192.
[12]
StedmanCA, BarclayML.
Review article: comparison of the pharmacokinetics, acid suppression and efficacy of proton pump inhibitors[J].
Aliment Pharmacol Ther,
2000,
14：
963–
978.
[13]
RayS, DelaneyM, MullerAF, et al.
Proton pump inhibitors and acute interstitial nephritis[J].
BMJ,
2010,
341：
c4412.
[14]
Toms-WhittleLM, JohnLH, BuckleyDA, et al.
Drug-induced subacute cutaneous lupus erythematosus associated with omeprazole[J].
Clin Exp Dermatol,
2011,
36：
281–
283.
[15]
TrögerU, ReicheI, JepsenMS, et al.
Esomeprazole-induced rhabdomyolysis in a patient with heart failure[J].
Intensive Care Med,
2010,
36：
1278–
1279.
[16]
TargownikLE, IAxLM, LeungS, et a1.
Proton-pump inhibitor use is not associated with osteoporosis or accelerated bone mineral density loss[J].
Gastroenterology,
2010,
138：
896–
904.
[17]
KayeJA, JickH.
Proton pump inhibitor use and risk of hip fractures in patients without major risk factors[J].
Pharmacotherapy,
2008,
28：
951–
959.
[18]
PhilipO, Katz, MD, LaurenB, et al.
Guidelines for the Diagnosis and management of gastroesophageal reflux disease[J].
Am J Gastroenterol,
2013,
108：
308–
328.
[19]
LeontiadisGI, MoayyediP.
Proton pump inhibitors and risk of bone fractures[J].
Curr Treat Options Gastroenterol,
2014,
12：
414–
423.
[20]
YangYX, LewisJD, EpsteinS, et al.
Long-term proton pump inhibitor therapy and risk of hip fracture[J].
JAMA,
2006,
296：
2947–
2953.
[21]
TargownikLE, LixLM, MetgeCJ, et al.
Use of proton pump inhibitors and risk of osteoporosis-related fractures[J].
CMAJ,
2008,
179：
319–
326.
[22]
VestergaardP, RejnmarkL, MosekildeL, et al.
Has mortality after a hip fracture increased[J]?
J Am Geriatr Soc,
2007,
55：
1720–
1726.
[23]
LiHB, ZhaoRS.
Evidence-based evaluation of fracture risk in clinical therapy with proton pump inhibitor[J].
Clinical Medication Journal,
2014，
12：
1–
8.
李慧博，赵荣生．
质子泵抑制剂临床治疗与骨折风险的循证评价[J]．
临床药物治疗杂志，
2014，
12：
1–
8.
[24]
China Food and Drug Administration(CFDA).
Alert the risk for fractures, hypomagnesaemia and the interactionwith clopidogrelof proton pump inhibitors.
Newsletter of Adverse Drug Reactions,
2013.
国家食品药品监督管理总局(CFDA)．
警惕质子泵抑制剂的骨折、低镁血症风险以及与氯吡格雷的相互作用．
药品不良反应信息通报，
2013.
http://www.sfda.gov.cn/WS01/CL0078/80914.html.
[25]
MadanickRD.
Proton pump inhibitor side effects and drug interactions: much ado about nothing？[J].
Cleve Clin J Med,
2011,
78：
39–
49.
[26]
LaheijRJ, SturkenboomMC, HassingRJ，et al.
Risk of community-acquired pneumonia and use of gastric acid-suppressive drugs[J].
JAMA,
2004,
292：
1955–
1960.
[27]
GulmezSE, HolmA, FrederiksenH, et al.
Use of proton pump inhibitors and the risk of community-acquired pneumonia: a population-based case-control study[J].
Arch Intern Med,
2007,
167：
950–
955.
[28]
HermosJA, YoungMM, FondaJR, et al.
Risk of community-acquired pneumonia in veteran patients to whom proton pump inhibitors were dispensed[J].
Clin Infect Di,
2012,
54：
33–
42.
[29]
RougheadEE, RamsayEN, PrattNL，et al.
Proton-pump inhibitors and the risk of antibiotic use and hospitalisation for pneumonia[J].
Med J Aust,
2009,
190：
114–
116.
[30]
EomCS, JeonCY, LimJW, et al.
Use of acid-suppressive drugs and risk of pneumonia: a systematic review and meta-analysis[J].
CMAJ,
2011,
183：
310–
319.
[31]
JohnstoneJ, NerenbergK, LoebM, et al.
Meta-analysis: proton pump inhibitor use and the risk of community-acquired pneumonia[J].
Aliment Pharmacol Ther,
2010,
31：
1165–
1177.
[32]
GiulianoC, WilhelmSM, PBKale-Pradhan, et al.
re proton pump inhibitors associated with the development of community-acquired pneumonia? A meta-analysis[J].
Expert Rev Clin Pharmacol,
2012,
5：
337–
344.
[33]
Kristian BFilion, DanChateau, Laura ETargownik，et al.
Proton pump inhibitors and the risk of hospitalisation for community-acquired pneumonia: replicated cohort studies with meta-analysis[J].
Gut,
2014,
63：
552–
558.
[34]
WilliamsC, McColl, KE.
Review article: proton pump inhibitors and bacterial overgrowth[J].
Aliment Pharmacol Ther,
2006,
23：
3–
10.
[35]
LeonardJ, MarshallJK, MoayyediP, et al.
Systematic review of the risk of enteric infection in patients taking acid suppression[J].
Am J Gastroenterol,
2007,
102：
2047–
56.
[36]
McDonaldEG, MilliganJ, FrenetteC，et al.
Continuous Proton Pump Inhibitor Therapy and the Associated Risk of Recurrent Clostridium difficile Infection[J].
JAMA,
2015,
175：
784–
791.
[37]
LinskyA, GuptaK, LawlerEV，et al.
Proton pump inhibitors and risk for recurrent Clostridium difficile infection[J].
Arch Intern Med,
2010,
170：
772–
778.
[38]
KimJW, LeeKL, JeongJB, et al.
Proton pump inhibitors as a risk factor for recurrence of Clostridium-difficile-associated diarrhea[J]．
World JGastroenterol,
2010,
16：
3573–
3577.
[39]
CadleRM, MansouriMD, LoganN, et al.
Association of proton-pump inhibitors with outcomes in Clostridium difficile colitis[J].
Am J Health Syst Pharm,
2007,
64：
2359–
2363.
[40]
DialS, AlrasadiK, ManoukianC，et al.
Risk of Clostridium difficile diarrhea among hospital inpatients prescribed proton pump inhibitors: cohort and case-control studies[J].
CMAJ,
2004,
171：
33–
38.
[41]
TleyjehIM, Bin AbdulhakAA, RiazM, et al.
Association between proton pump inhibitor therapy and clostridium difficile infection: a contemporary systematic review and meta-analysis[J]．
PLoS One,
2012，
7：
e50836.
[42]
Edward sheen，George, Triadafilopoulos.
Adverse Effects of Long-Term Proton Pump Inhibitor Therapy[J].
Dig Dis Sci,
2011,
56：
931–
950.
[43]
SarzynskiE, PuttarajappaC, XieY, et al.
Association between proton pump inhibitor use and anemia: a retrospective cohort study[J].
Dig Dis Sci,
2011,
56：
2349–
2353.
[44]
McCollKE.
Effect of proton pump inhibitors on vitamins and iron[J].
Am J Gastroenterol,
2009,
104
Suppl 2：
S5–
9.
[45]
AllenRH, SeetharamB, PodellE, et al.
Effect of proteolytic enzymes on the binding of cobalamin to R protein and intrinsic factor. In vitro evidence that a failure to partially degrade R protein is responsible for cobalamin malabsorption in pancreatic insufficiency[J].
J Clin Invest,
1978，
61：
47–
54.
[46]
HirschowitzBI, WorthingtonJ, MohnenJ, et al.
Vitamin B12 deficiency in hypersecretors during long-term acid suppression with proton pump inhibitors[J].
Aliment Pharmacol Ther,
2008,
27：
1110–
1121.
[47]
Den ElzenWP, GroeneveldY, De RujiterW, et al.
Long-term use of proton pumpinhibitors and vitamin B12 status in elderly individuals[J].
Aliment Pharmacol Ther,
2008，
27：
491–
497.
[48]
TohJW, OngE, WilsonR, et al.
Hypomagnesaemia associated with long-term use of proton pump inhibitors[J].
Gastroenterology Report(Oxf)，
2015，
3：
245–
253.
[49]
LiuGF.
Long-term use of proton pump inhibitor and hypomagnesemia[J].
Chin J Dig,
2013，
33：
497–
499.
刘改芳．
长期应用质子泵抑制剂与低镁血症[J]．
中华消化杂志，
2013，
33：
497–
499.
[50]
LemonTI.
Proton pump inhibitors and hypomagnesemia monitoring[J]．
Int J Gen Med,
2013，
6：
675.
[51]
StolteM.
Fundic gland polyps: a rare, innocuous, and reversible disturbance[J].
Gastroenterology,
1993，
105：
1590–
1591.
[52]
WedemeyerRS, BlumeH.
Pharmacokinetic Drug Interaction Profiles of Proton Pump Inhibitors: An Update[J].
Drug Saf,
2014,
37：
201–
211.
[53]
LabenzJ, PetersenKU，RöschW，et al.
A summary of Food and Drug Administration-reported adverse events and drug interactions occurring during therapy with omeprazole, lansoprazole and pantoprazole[J].
Aliment Pharmacol Ther,
2003，
17：
1015–
1019.
[54]
Luis MoreiraDias.
Pantoprazole A Proton Pump Inhibitor[J].
Clin Drug Investig,
2009,
29
Suppl 2：
S3–
12.
[55]
GoirandF, Le RayI, BardouM, et al.
Pharmacokinetic evaluation of esomeprazole for the treatment of gastroesophageal reflux disease. Expert Opin[J].
Drug Metab Toxicol,
2014，
10：
1301–
1311.
[56]
HoPM, MaddoxTM, WangL, et al.
Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome[J].
JAMA,
2009,
301：
937–
944.
[57]
BanerjeeS, WeidemanRA, WeidemanMW, et al.
Effect of concomitant use of clopidogrel and proton pump inhibitors after percutaneous coronary intervention[J].
Am J Cardiol,
2011,
107：
871–
878.
[58]
AlkhatibAA, ElkhatibFA, KhatibOF, et al.
Gastric acid-reducing medications and clopidogrel: what are the latest FDA recommendations[J]．
Am J Gastroenterol,
2010,
105：
1211.
[59]
BhattDL, CryerBL, ContantCF，et al.
Clopidogrel with or without omeprazole in coronary artery disease[J].
N Engl J Med,
2010,
363：
1909–
1917.
[60]
O'DonoghueML, BraunwaldE, AntmanEM，et al.
Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor：an analysis of two randomised trials[J].
Lancet,
2009,
374：
989–
997.
[61]
WangR, LiYJ.
The effect of proton pump inhibitors on the patients with dual antiplatelet therapy after Percutaneous Coronary Interventions[J].
China Medicine,
2013，
8：
10–
11.
王悦，李雅君．
质子泵抑制剂对冠心病患者经皮冠状动脉介入术后双重抗血小板治疗的影响[J]．
中国医药，
2013，
8：
10–
11.
[62]
GersonLB, McMahonD, OlkinI, et al.
Lack of Significant Interactions Between Clopidogrel and Proton Pump Inhibitor Therapy: Meta-Analysis of Existing Literature[J].
Dig Dis Sci,
2012,
57：
1304–
1313.
[63]
SharvariM, BhurkeB, PharmMS, et al.
Effect of the clopidogrel-proton pump inhibitor drug interaction on adverse cardiovascular events in patients with acute coronary syndrome[J].
Pharmacotherapy,
2012,
32：
809–
818.
[64]
Chinese Society of Gastroenterology.
The Chinese Expert Consensus on Gastroesophageal reflux disease[J].
Chin J Dig,
2014,
34：
649–
661.
中华医学会消化病学分会．
2014年中国胃食管反流病专家共识意见[J]．
中华消化杂志，
2014,
34：
649–
661.
[65]
KatelarisPH, SeowF, LinBP, et al.
Effect of age, Helicobacter pylori infection, and gastritis with atrophy on serum gastrin and gastric acid secretion in healthy men[J].
Gut,
1993,
34：
1032–
1037.
[66]
GoldschmiedtM, BarnettCC, SchwarzBE, et al.
Effect of age on gastric acid secretion and serum gastrin concentrations in healthy men and women[J].
Gastroenterology,
1991,
101：
977–
990.
[67]
WuBY, WangMW, LiY.
The features of 24-hour intragastric pH in the aged[J].
Chin J Geriatr,
1999,
18：
147–
150.
吴本俨，王孟薇，李园．
老年人24小时胃内pH节律变化特点[J]．
中华老年医学杂志，
1999,
18：
147–
150.
[68]
ZhengSB, XiangP, XuFX, et al.
The change of fasting gastric fluidandIntragastric acidity with the age increasing[J].
Chin J Geriatr,
2008,
27：
283.
郑松柏，项平，徐富星，等．
空腹胃液量及胃内酸度的增龄变化[J]．
中华老年医学杂志，
2008,
27：
283.
[69]
ZhangW, ZhengSB, ZhuangY, et al.
H＋ /K＋ ATPase expression in human parietal cells and gastric acid secretion in elderly individuals[J].
J Dig Dis，
2013,
14：
366–
372.
[70]
HurwitzA, BradyDA, SchaalSE, et al.
Gastric acidity in older adults[J].
JAMA,
1997,
278：
659–
662.
[71]
ZhangY, ZhengSB.
The modern understanding of gastric acid in the elderly[J].
Geriatr Health Care,
2012,
18：
186–
189.
庄艳，郑松柏．
老年人胃酸的现代认识[J]．
老年医学与保健，
2012，
18：
186–
189.
[72]
ThjodleifssonB.
Treatment of Acid-Related Diseases in the Elderly with Emphasis on the Use of Proton Pump Inhibitors[J].
Drugs Aging,
2002,
19：
911–
927.
[73]
BaldiF.
Lansoprazole Oro-Dispersible tablet pharmacokinetics and therapeutic use in acid-related disorders[J].
Drugs，
2005，
65：
1419–
1426.
[74]
ZhengSB.
The characteristics of gastroesophageal reflux disease in the elderly[J].
Chin J Geriatr,
2009，
28：
265–
266.
郑松柏．
老年人胃食管反流病的特点[J]．
中华老年医学杂志，
2009,
28：
265–
266.
[75]
Chinese Journal of Digestion Editorial Board.
Recommend of diagnosis and treatment for peptic ulcer disease(2013, Shen Zhen)[J].
Chin J Dig,
2014,
34：
73–
76.
中华消化杂志编委会．
消化性溃疡病诊断与治疗规范建议(2013年，深圳)．
中华消化杂志，
2014,
34：
73–
76.
[76]
National Medical Journal of China Editorial Board.
Recommend of prevention and treatment for Stress Ulcer[J].
Chin J Dig,
2002，
82：
1000–
1001.
中华医学杂志编辑委员会．
应激性溃疡防治建议[J]．
中华医学杂志，
2002，
82：
1000–
1001.
[77]
The Editorial Board of Chinese Journal of Internal Medicine, the Editorial Board of Chinese Journal of Digestive Diseases, the Editorial Board of Chinese Journal of Digestive Endoscopy.
Diagnosis and treatment guidelines for acute nonvariceal upper gastrointestinal bleeding(2009, Hang Zhou)[J].
Chin J Intern Med,
2009,
48：
891–
894.
《中华内科杂志》编委会，《中华消化杂志》编委会，《中华消化内镜杂志》编委会．
急性非静脉曲张性上消化道出血诊治指南(2009，杭州)[J]．
中华内科杂志，
2009,
48：
891–
894.
[78]
YuanZY, YangYS, WuKC.
Understanding of Management of Patients With Ulcer Bleeding in 2012 and Clinical application for proton pump inhibitors[J].
Chin J Dig,
2012,
2：
487–
489.
袁耀宗，杨云生，吴开春.
2012年《溃疡出血患者处理指南》的解读与质子泵抑制剂的临床应用[J]．
中华消化杂志，
2012,
2：
487–
489.
[79]
Chinese Helicobacter pylori Research Group, Chinese Society Of Gastroenterology.
The fourth national consensus report about treatment of Helicobacter pylori infection[J].
Chin J Med,
2012,
51：
832–
837.
中华医学会消化病学分会幽门螺杆菌学组/全国幽门螺杆菌协作组．
第四次全国幽门螺杆菌感染处理共识报告[J]．
中华内科杂志，
2012,
51：
832–
837.
[80]
WuKC, LiuZX.
Nonsteroidal antiinflammatory drugs and peptic ulcer disease[J].
Chin J Dig,
2008,
28：
439–
441.
吴开春，刘震雄．
非甾体类抗炎药与消化性溃疡[J]．
中华消化杂志，
2008,
28：
439–
441.
[81]
ZhuQ, XiongHF, WuW, et al.
Survey on the clinical use of nonsteroidal antiinflammatory drugs in China[J].
Chin J Dig,
2008,
28：
842–
846.
诸琦，熊慧芳，吴巍．
非甾体类抗炎药临床应用调查[J]．
中华消化杂志，
2008,
28：
842–
846.
[82]
IwamotoJ, SaitoY, HondaA, et al.
Clinical features of gastroduodenal injury associated with long-term low-dose aspirin therapy[J].
World J Gastroenterol,
2013,
19：
1673–
1682.
[83]
Chinese expert consensus group of prevention and treatment for antiplatelet drug related digestive tract damage.
Chinese expert consensus on prevention and treatment for antiplatelet drug related digestive tract damage(update in 2012)[J].
Chin J intern Med,
2013,
52：
264–
270.
抗血小板药物消化道损伤的预防和治疗中国专家共识组．
抗血小板药物消化道损伤的预防和治疗中国专家共识(2012更新版)[J]．
中华内科杂志，
2013,
52：
264–
270.
[84]
CryerB, BhattDL, LanzaFL, et al.
Low-dose aspirin-induced ulceration is attenuated by aspirin-phosphatidylcholine: a randomized clinical trial[J].
Am J Gastroenterol,
2011,
106：
272–
277.
[85]
LanzaFL, ChanFK, QuigleyEM，et al.
Guidelines for prevention of NSAID-related ulcer complications[J].
Am J Gastroenterol,
2009,
104：
728–
738.
[86]
RostomA, MoayyediP, HuntR, et al.
Canadian consensus guidelines on long-term nonsteroidal anti-inflammatory drug therapy and the need for gastroprotection: benefits versus risks[J].
Aliment Pharmacol Ther,
2009,
29：
81–
96.
[87]
RostomA, DubeC, WellsG, et al.
Prevention of NSAID-induced gastroduodenal ulcers[J].
Cochrane Database Syst Rev，
2002，：
CD002296.
[88]
BhattDL, CryerBL, ContantCF, et al.
Clopidogrel with or without omeprazole in coronary artery disease[J].
N Engl J Med,
2010,
363：
1909–
1917.
[89]
ChristensenS, RiisA, NrgaardM, et al.
Perforated peptic ulcer: use of pre-admission oral glucocorticoids and 30-day mortality[J].
Aliment Pharmacol Ther,
2006,
23：
45–
52.
[90]
LeeHC, ChoDY, LeeWY, et al.
Pitfalls in treatment of acute cervical spinal cord injury using high-dose methylprednisolone: a retrospect audit of 111 patients[J].
Surg Neurol,
2007，
68
Suppl：
S37–
42.
[91]
ParkCH, LeeSK.
Preventing and controlling bleeding in gastric endoscopic submucosal dissection[J].
Clin Endosc,
2013,
46：
456–
462.
[92]
ZhaoF, YangJM.
Treatment for the ulcer after endoscopic submucosal dissection[J].
Chin J Clinicians(Electronic Edition),
2013,
7：
9014–
9016.
赵飞，杨建民．
内镜黏膜下剥离术后溃疡的治疗[J]．
中华临床医师杂志(电子版),
2013,
7：
9014–
9016.
[93]
Chinese Society Of Gastroenterology.
Chinese expert consensus on Chronic Gastritis(2012, Shang Hai)[J]．
Chin J Dig,
2013,
33：
5–
16.
中华医学会消化病学分会，
中国慢性胃炎共识意见(2012年，上海)[J],
中华消化杂志，
2013,
33：
5–
16.
[94]
MiwaH, GhoshalUC, FockKM, et al.
Asian consensus report on functional dyspepsia[J].
J Gastroenterol Hepatol,
2012,
27：
626–
641.
[95]
MiwaH, KusanoM, ArisawaT，et al.
Evidence-based clinical practice guidelines for functional dyspepsia[J].
J Gastroenterol，
2015,
50：
125–
139.
[96]
Chinese Society Of Geriatrics，Chinese Journal of Geriatrics Editorial Board.
Expert consensus on diagnosis and treatment for functional dyspepsia in the elderly[J].
Chin J Geriatr,
2015,
34：
698–
705.
中华医学会老年医学分会，中华老年医学杂志编委会．
老年人功能性消化不良诊治专家共识[J]．
中华老年医学杂志，
2015,
34：
698–
705.
